Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

@inproceedings{Kal2017PatientAT,
  title={Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region},
  author={Zolt{\'a}n Kal{\'o} and Zolt{\'a}n Vok{\'o} and Andrew J. K. {\"O}st{\"o}r and Emma Clifton-Brown and Radu S Vasilescu and Alysia Battersby and Edward Gibson},
  booktitle={Journal of market access & health policy},
  year={2017}
}
Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted healthcare budgets. This study compares the size of RA patient populations with access to reimbursed bDMARDs across 37 European countries, Russia, and Turkey, according to their treatment eligibility… CONTINUE READING
2 Citations
22 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 22 references

GDP per capita, PPP (current international $)

  • World Bank
  • 2015
2 Excerpts

Health expenditure, public (% of GDP)

  • World Bank
  • Available from:http://data.worldbank. org…
  • 2013
2 Excerpts

Similar Papers

Loading similar papers…